EPIRUBICINE MEDAC 2 mg/ml

DRUG2 trials

Sponsors

Institut Paoli Calmettes

Conditions

Breast cancertriple‑negative breast cancer

Phase 2

PELICAN-IPC 2015-016 A prospective, multicentre, open-label, randomized, Phase II study of Pembrolizumab in combination with neo-adjuvant EC-Paclitaxel regimen in HER2-negative inflammatory Breast Cancer

Not yet recruitingCTIS2024-514899-41-00

Institut Paoli CalmettesBreast cancer

Target: 72Updated: 2024-10-31

DECREASE-IPC 2025-068 : De-Ecalating neoadjuvant Chemoimmunotherapy in early triple-negative BREASt cancer

Not yet recruitingCTIS2025-525040-18-00

Institut Paoli Calmettestriple‑negative breast cancer

Target: 84Updated: 2026-07-24